Analysts See $-0.25 EPS for Endologix, Inc. (ELGX)

October 13, 2018 - By Peter Kolinski

Endologix, Inc. (NASDAQ:ELGX) LogoInvestors sentiment increased to 1.35 in 2018 Q2. Its up 0.49, from 0.86 in 2018Q1. It increased, as 3 investors sold Endologix, Inc. shares while 31 reduced holdings. 19 funds opened positions while 27 raised stakes. 77.82 million shares or 4.16% less from 81.20 million shares in 2018Q1 were reported.
Amalgamated Bancorp stated it has 0% in Endologix, Inc. (NASDAQ:ELGX). Nea Ltd owns 0.66% invested in Endologix, Inc. (NASDAQ:ELGX) for 2.49 million shares. Palisade Mgmt Ltd Llc Nj reported 1.62M shares or 0.27% of all its holdings. Partner Inv Mngmt Limited Partnership reported 84,075 shares or 0.38% of all its holdings. Prns Llc reported 0.05% in Endologix, Inc. (NASDAQ:ELGX). American Interest Grp Inc, New York-based fund reported 54,171 shares. Element Mngmt Ltd Limited Liability Company stated it has 30,433 shares or 0% of all its holdings. Savings Bank Of Mellon accumulated 358,670 shares. 54,759 were accumulated by Credit Suisse Ag. Tiaa Cref Mgmt Ltd Limited Liability Company holds 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX) for 288,034 shares. Axa holds 959,836 shares. Arrowmark Colorado Lc stated it has 9.91 million shares. Lombard Odier Asset Mgmt (Usa) accumulated 800,000 shares or 0.3% of the stock. Morgan Stanley has 189,795 shares. Art Advisors Lc stated it has 16,633 shares.

Since May 29, 2018, it had 1 insider buy, and 1 insider sale for $72,809 activity. Chavez Christopher G. also sold $91 worth of Endologix, Inc. (NASDAQ:ELGX) on Tuesday, May 29.

Analysts expect Endologix, Inc. (NASDAQ:ELGX) to report $-0.25 EPS on November, 6.They anticipate $0.14 EPS change or 127.27 % from last quarter’s $-0.11 EPS. After having $-0.18 EPS previously, Endologix, Inc.’s analysts see 38.89 % EPS growth. The stock decreased 1.79% or $0.03 during the last trading session, reaching $1.65. About 479,296 shares traded. Endologix, Inc. (NASDAQ:ELGX) has declined 55.38% since October 14, 2017 and is downtrending. It has underperformed by 71.00% the S&P500.

Endologix, Inc. (NASDAQ:ELGX) Ratings Coverage

Among 4 analysts covering Endologix Inc (NASDAQ:ELGX), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Endologix Inc had 4 analyst reports since April 25, 2018 according to SRatingsIntel. The stock has “Market Perform” rating by BMO Capital Markets on Monday, August 13. On Monday, May 21 the stock rating was maintained by Stifel Nicolaus with “Hold”. The company was downgraded on Friday, August 10 by PiperJaffray.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company has market cap of $139.77 million. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. It currently has negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.

More important recent Endologix, Inc. (NASDAQ:ELGX) news were published by: Seekingalpha.com which released: “Endologix sees Q3 revenue as high as $34.7M; shares up 1% after hours” on October 02, 2018, also Streetinsider.com published article titled: “Pre-Open Movers 10/03: (ELGX) (JCP) (TPX) Higher; (DTEA) (CENX) (KALA) Lower (more…)”, Seekingalpha.com published: “Key events next week – healthcare” on September 28, 2018. More interesting news about Endologix, Inc. (NASDAQ:ELGX) was released by: Businesswire.com and their article: “FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall” with publication date: October 05, 2018.

Endologix, Inc. (NASDAQ:ELGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>